These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447 [TBL] [Abstract][Full Text] [Related]
11. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600 [TBL] [Abstract][Full Text] [Related]
12. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Decaudin D; Brousse N; Brice P; Haioun C; Bourhis JH; Morel P; Van Hoof A; Souleau B; Quesnel B; Gisselbrecht C Bone Marrow Transplant; 2000 Feb; 25(3):251-6. PubMed ID: 10673695 [TBL] [Abstract][Full Text] [Related]
14. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Kyriakou C; Canals C; Sibon D; Cahn JY; Kazmi M; Arcese W; Kolbe K; Gorin NC; Thomson K; Milpied N; Niederwieser D; Indrák K; Corradini P; Sureda A; Schmitz N J Clin Oncol; 2010 May; 28(13):2227-32. PubMed ID: 20368570 [TBL] [Abstract][Full Text] [Related]
15. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI; Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879 [TBL] [Abstract][Full Text] [Related]
16. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH; Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078 [TBL] [Abstract][Full Text] [Related]